

Abby Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1867310/publications.pdf>

Version: 2024-02-01

28
papers

565
citations

566801

15
h-index

610482

24
g-index

28
all docs

28
docs citations

28
times ranked

628
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada. <i>American Journal of Perinatology</i> , 2022, 39, 1668-1677. | 0.6 | 8 |
| 2 | What risk factors for sudden infant death syndrome are preterm and term medically complex infants exposed to at home?. <i>Paediatrics and Child Health</i> , 2021, 26, e184-e188. | 0.3 | 1 |
| 3 | Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 539-545. | 1.1 | 7 |
| 4 | Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 694-699. | 1.1 | 8 |
| 5 | A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab. <i>American Journal of Perinatology</i> , 2020, 38, e129-e136. | 0.6 | 0 |
| 6 | Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2020, 267, 185-190. | 2.0 | 13 |
| 7 | Use of Palivizumab in Canada; Data from the CARESS registry 2005-2017. <i>Paediatrics and Child Health</i> , 2019, 24, e28-e28. | 0.3 | 0 |
| 8 | Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 775-780. | 1.1 | 6 |
| 9 | Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1113-1118. | 1.3 | 8 |
| 10 | Adherence and outcomes: a systematic review of palivizumab utilization. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 27-42. | 1.0 | 31 |
| 11 | Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015). <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 445-450. | 1.1 | 15 |
| 12 | Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 2-8. | 1.1 | 28 |
| 13 | First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015). <i>European Journal of Pediatrics</i> , 2017, 176, 413-422. | 1.3 | 12 |
| 14 | Palivizumab Adherence and Outcomes in Canadian Aboriginal Children. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 1187-1193. | 1.1 | 3 |
| 15 | Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e290-e297. | 1.1 | 35 |
| 16 | Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. <i>PLoS ONE</i> , 2015, 10, e0134711. | 1.1 | 20 |
| 17 | Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, e29-e33. | 1.1 | 25 |
| 18 | Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study. <i>Pediatrics</i> , 2014, 133, 1031-1037. | 1.0 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Predictors of readmission to a psychiatry inpatient unit. <i>Comprehensive Psychiatry</i> , 2014, 55, 426-430. | 1.5 | 36 |
| 20 | Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005-2012) Compared to Other International Registries. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-15. | 3.3 | 34 |
| 21 | CARESS. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 213. | 1.1 | 3 |
| 22 | Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease Relieve Caregiver Burden?. <i>Drugs and Aging</i> , 2012, 29, 167-179. | 1.3 | 33 |
| 23 | A review of the effectiveness of palivizumab for respiratory syncytial virus. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 553-567. | 0.7 | 20 |
| 24 | Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. <i>European Journal of Pediatrics</i> , 2012, 171, 833-841. | 1.3 | 37 |
| 25 | Memantine in dementia: a review of the current evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 787-800. | 0.9 | 53 |
| 26 | CARESS: The Canadian Registry of Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 651-655. | 1.1 | 44 |
| 27 | Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. <i>International Psychogeriatrics</i> , 2011, 23, 539-545. | 0.6 | 25 |
| 28 | Are Vascular Risk Factors Associated With Post-Stroke Depressive Symptoms?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011, 24, 215-221. | 1.2 | 18 |